GlaxoSmithKline Plc, AstraZeneca Plc And The Pharma Fightback

Looking at AstraZeneca plc (LON:AZN) and GlaxoSmithKline plc (LON:GSK, is pharma’s decline finally over?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Pharmaceuticals have long been seen as an industry whose best days are past. New drugs blockbusters seem fewer and further between, with a constantly diminishing return from innovation. And the current blockbusters seem to be hurtling over the edge of the infamous ‘patent cliff’.

Is pharma really an industry in decline?

As profits lost from patent expiries overtake the profits gained from new drugs, Big Pharma seems to be an industry in decline.

Because of this apparent malaise in the industry, share prices have fallen to bargain levels. Yet, let’s dig a little deeper. Is pharma really an industry in decline? Not in my eyes.

The global population is steadily increasing, and the world is aging. As emerging and frontier markets boom, the new middle classes will spend more and more of their income on healthcare, and particularly on drug treatments.

The boom in healthcare technologies

But surely most of the drugs bought these days are off-patent and thus cheap? I think you underestimate the ingenuity and creativity of mankind. As the boom in chemical drugs draws to a close, we have instead a boom in biologics, as the worlds of pharma and biotech collide.

That’s not to mention the explosion in genetic technologies, the growth in stem cell science, and myriad other medical technologies. As the pharma industry invests in these areas, they will find a range of ways of advancing global healthcare.

That’s why the pharmaceutical industry has been one of the contrarian picks of recent years. Finally, finally, the market seems to have woken up to this. In recent months, the share prices of British drugs giants GlaxoSmithKline (LSE: GSK) and AstraZeneca (LSE: AZN) have broken out of their trading ranges and are climbing steadily higher.

The fightback is on

I hold GlaxoSmithKline as I feel this is the pharma company that really has cracked innovation, and the proof of this is its buzzing drugs pipeline. I would say that AstraZeneca is also a worthy investment, with chief executive Pascal Soriot settling down to the weighty task of turning around this drugs titan.

Pharmaceutical company share prices are surging, and I suspect they will climb higher. Pharma really is fighting back.

Neil Woodford was one of the few fund managers to see the contrarian opportunity that was the pharmaceutical industry. He could see that Big Pharma was incredibly cheap, and that fears over its decline were overplayed. And his bet on the pharmaceutical industry is now paying dividends.

Want to learn more about the contrarian maestro’s recent share picks? Then simply read our free report by clicking on “The FTSE Shares That Britain’s Super-Investor Owns”.

> Prabhat owns shares in GlaxoSmithKline.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

More on Investing Articles

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

Why the FTSE 250 looks an incredible bargain

While all the attention is on the elite FTSE 100, the mid-cap FTSE 250 index looks unbelievably cheap. I don't…

Read more »

2024 year number handwritten on a sandy beach at sunrise
Investing Articles

Here’s my plan to make the most of juicy UK shares ahead of 2024 and beyond!

Our writer reckons there hasn't been a better time to snap up quality UK shares. She explains how she's planning…

Read more »

Young Black woman using a debit card at an ATM to withdraw money
Investing Articles

Here’s how many Lloyds shares I’d need to buy for a £100 monthly income!

Offering a higher dividend yield than the average across FTSE 100 stocks, are Lloyds shares worth buying for passive income…

Read more »

Playful senior couple in aprons dancing and smiling while preparing healthy dinner at home
Investing Articles

Up 27% in 2023, what next for the Tesco share price in 2024?

The Tesco share price has had a great 2023, rising 27% while the FTSE 100 was flat. But what might…

Read more »

Hand is turning a dice and changes the direction of an arrow symbolizing that the value of an ETF (Exchange Traded Fund) is going up (or vice versa)
Investing Articles

FTSE 250? No, I’d buy this index fund instead

Investing in index funds can be a profitable enterprise. Our author has been exploring the different options to determine the…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

This 4% yielding FTSE 100 giant is dirt-cheap and perfect for passive income!

Looking for a mammoth business with shares trading at discount levels and offering an excellent passive income opportunity? Our writer…

Read more »

UK money in a Jar on a background
Investing Articles

Here’s how I’d use dividend shares to try and turn £5,000 of savings into passive income of £900 a year

With dividend shares at today’s prices, Stephen Wright thinks there are two ways to turn a £5,000 investment into something…

Read more »

Investing Articles

After a recovery that Lazarus would have been proud of, is the easyJet share price worth a look?

With its dividend restored and its balance sheet repaired, the easyJet share price looks like a bargain. But Stephen Wright…

Read more »